Press Release Mar 23 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Letermovir tablets in two dosages. The tablets are intended to prevent disease caused by cytomegalovirus in patients who have undergone bone marrow or kidney transplants. The manufacturing will take place at Zydus's facility in Ahmedabad SEZ, India. The press release also notes that Letermovir tablets had significant annual sales in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 16 2024
- Press Release Mar 14 2024
- Press Release Mar 13 2024
- Press Release Feb 26 2024
- Press Release Feb 16 2024
Later from Zydus Lifesciences
- Press Release Apr 01 2024
- Press Release Apr 20 2024
- Zydus Lifesciences Limited Press Release Apr 22 2024
- Press Release Apr 23 2024
- Press Release Apr 26 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences